Using advanced MRI to diagnose brain tumors
Correlation of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging and Tumor Histopathology in Patients With Infiltrating Gliomas
This study is testing a new type of MRI to see if it can better identify brain tumors called infiltrating gliomas in patients who are about to have surgery.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 5 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | University of Maryland, Baltimore Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT04772456 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the safety and feasibility of hyperpolarized metabolic MRI for diagnosing infiltrating gliomas, a type of brain tumor. It will assess how accurately this advanced imaging technique can identify these tumors compared to standard MRI methods. The study will involve up to 5 patients at the University of Maryland, Baltimore, who have suspected infiltrating gliomas or a history of such tumors and are scheduled for surgery. The FDA has approved the use of hyperpolarized 13C-pyruvate in this investigation.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-80 with suspected infiltrating gliomas or a history of such tumors who can undergo MRI.
Not a fit: Patients unable to undergo MRI or those with severe reactions to IV contrast may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses of infiltrating gliomas, potentially improving treatment outcomes.
How similar studies have performed: While this approach is innovative, similar studies using advanced MRI techniques have shown promise in other contexts, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Patients with a new brain lesion interpreted as suspected infiltrating gliomas including but not limited to (diffuse astrocytoma WHO grade 2; oligodendroglioma WHO grade 2 and 3; anaplastic astrocytoma WHO grade 3; astrocytoma WHO grade 4), OR, patients with prior history of infiltrating glioma scheduled for surgery for tumor biopsy or resection. * Ages 18-80, including male and female * Suitable to undergo contrast-enhanced MRI * Negative serum pregnancy test Exclusion Criteria: * Inability to undergo MRI scan * Inability to receive IV contrast secondary to severe reaction or renal insufficiency.
Where this trial is running
Baltimore, Maryland
- Rosy Njonkou Tchoquessi — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Dirk Mayer, Dr. rer. nat — University of Maryland, Baltimore
- Study coordinator: Rosy Njonkou Tchoquessi
- Email: rnjonkou@som.umaryland.edu
- Phone: 4107066445
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.